Clinical value:
1. E7 protein is direct evidence of cervical cancer carcinogenesis, so a positive E7 protein test can effectively indicate the risk of cervical cancer.
2. The expression of E7 protein precedes changes in cellular morphology, so combining E7 protein detection with cytology/HPV screening can effectively improve the accuracy and efficiency of cervical cancer screening, thereby avoiding overdiagnosis in ASC-US and LSIL women.
3.When there is a transient infection, HPV virus exists in a free state and E7 protein is not expressed. When sustained infection occurs, viral DNA integrates into the host cell genome, and E6/E7 oncogenes remain highly expressed, driving malignant transformation of the cell. Therefore, E7 protein testing can avoid overdiagnosis caused by transient HPV infection and accurately triage.
4.E7 protein can serve as a prognostic indicator for abnormal screening results, vaginal colposcopy, and post-treatment outcomes.
5.Compared to cell morphology testing, the results of E7 protein immunohistochemical staining are more intuitive and clear, making it easier for clinical doctors to interpret the results.
6.At present, the expert consensus and guidelines have not mentioned the detection of E7 protein in cervical precancerous lesions. However, with the accumulation of clinical research data on E7 protein, it is expected that the application of E7 protein detection will be added to the expert consensus and guidelines in the future.
Product Specifications
Human Papillomavirus (HPV) E7 Protein Antibody Reagent - Immunohistochemical Method
Main biomarke：AFT-002 E7 Affibody
Sample type: cervical tissue, cervical exfoliated cells
Detection method: Immunohistochemical method
Specifications: 3m/bottle (for 20 people), 15m bottle (for 100 people)
Supporting instruments：
Ly-mz36
Ly-m48
